Methods of treatment using mutant FGF-21 peptide conjugates
US12037376B2 · kind B2 · utility
0Cited by
9References
36Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 16, 2022 |
| Grant date | Jul 16, 2024 |
| Priority date | — |
| Expiry date | Jun 16, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Therapeutic regimens and uses of mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugates comprising a polyethylene glycol (PEG) moiety attached to a mutant FGF-21 peptide via a glycosyl moiety thereof in the treatment of nonalcoholic steatohepatitis are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.